Day: June 23, 2020

SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The decision was made after assessing the totality of the data including the 500 mg cohort, the highest dose studied in the trial.“Although vecabrutinib continues to exhibit an excellent safety profile, there is insufficient evidence of activity in BTK-inhibitor resistant B-cell malignancies to advance the drug into the planned Phase 2 portion of the trial. One partial remission was observed after 11 treatment cycles in a CLL patient treated in Cohort 5 (300 mg BID) and a number...

Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001)Women receiving relugolix combination therapy, on average, had a 73.3% reduction on the Numerical Rating Scale for dysmenorrhea from 7.3 (severe pain) to 1.8 (mild pain)Achieved all seven key secondary endpoints, including dyspareunia (painful intercourse) and a greater proportion of women not using opioids, with a generally well-tolerated safety profile including minimal bone mineral density lossConference call and webcast to be held today at 8:30 a.m. EDT / 5:30 a.m. PDTBASEL, Switzerland, June 23, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced top-line results from SPIRIT 1, the second of...

NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) — Travelzoo® (NASDAQ: TZOO):About TravelzooTravelzoo® provides our 30 million members insider deals and one-of-a-kind experiences personally reviewed by one of our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. For over 20 years we have worked in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.

TROY, Mich., June 23, 2020 (GLOBE NEWSWIRE) — Prior to the COVID-19 pandemic, U.S. schools were able to fill just 54 percent of the approximately 250,000 teacher absences each day. As many schools reopen in the fall, they will face a growing number of teacher absences due to the pandemic, exacerbating the teacher shortage. Twelve percent of teachers say the pandemic may lead them to leave the profession even though they were not planning to do so before the crisis.As district leaders look to fill classrooms, substitute teachers can bridge the gap, but key changes are needed to help recruit and retain substitutes as the demand for them increases in the era of school re-openings, according to a report from the EdWeek Research Center commissioned by Kelly Education.“Prior to the pandemic, schools across the country were already facing...

RIO VISTA, Calif., June 23, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) today announced the groundbreaking of Club Liberty, the 4.5-acre amenity center at Summit at Liberty, a 55+ community, in Rio Vista, California.Development is underway for Club Liberty, a $9 million amenity complex located within the gated Summit at Liberty community. At Club Liberty, residents will have endless opportunities for discovering new hobbies, socializing and staying active. This one-of-a-kind amenity center will include several gathering spaces, a state-of-the-art fitness studio, a resort-style pool and a community garden.Within Club Liberty, The Ranch House will serve as the central gathering space for homeowners to participate in activities with other residents. The Ranch House is also home to the Liberty House Café, several multi-purpose...

BUFFALO, N.Y., June 23, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the promotion of Teresa Bair, Esq. to Executive Officer as General Counsel and Senior Vice President, Administration.  She will report to Athenex’s Chief Executive Officer.Ms. Bair, who has more than 23 years of private and in-house legal experience, advances from the position of Senior Vice President, Legal Affairs and Administration.  Since joining Athenex in 2015, she has held various roles with increasing responsibility.  As General Counsel, she will continue overseeing all legal matters of the Company worldwide and serving as Corporate Secretary to the Board of Directors. ...

RAMSEY, N.J. and BOCA RATON, Fla., June 23, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the proposed resolution to elect Martha J. Demski to its Board of Directors was approved at the Company’s recent Annual Shareholder Meeting, held June 18, 2020. Ms. Demski brings over 35 years of experience in leading business growth and financial strategies for life sciences companies.  She currently serves as the Chairman of the Board of Chimerix, Inc., as well as a Board member for several life science companies including Adamas Pharmaceuticals and Equillium, Inc.“Martha has a long track record of success serving in executive leadership roles in both finance...

SLS-002 Was Safe and Well Tolerated Across All Doses with Resolution of Expected Group Mean Dissociative Side-Effects That Occurred in the Higher Dose Groups Within One HourNEW YORK, June 23, 2020 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced final safety data from its Phase I pharmacokinetics/pharmacodynamics (PK/PD) Study of Intranasal Racemic Ketamine (SLS-002) as well as the planned design of a double blind, placebo-controlled Proof of Concept (PoC) study for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD) to begin in the fall of 2020.All doses were safe and well tolerated.There were no new or unique safety signals.There...

REDWOOD CITY, Calif. and SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announce a partnership to engineer enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA.Under the terms of the agreement, Codexis will purchase $1 million in Series A preferred stock of Molecular Assemblies, and John Nicols, Codexis’ President and CEO will join the Molecular Assemblies’ Board of Directors. Furthermore, by applying its CodeEvolver® platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis, Codexis is eligible to earn additional Series A preferred stock that is expected,...